Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;31(22):3245-3264.
doi: 10.2174/0929867331666230717154101.

Potential Drugs in COVID-19 Management

Amin Gasmi  1 , Sadaf Noor  2 , Alain Menzel  3 , Nataliia Khanyk  4   5 , Yuliya Semenova  6 , Roman Lysiuk  4   5 , Nataliya Beley  7 , Liliia Bolibrukh  8 , Asma Gasmi Benahmed  9 , Olha Storchylo  10 , Geir Bjørklund  11
Affiliations
Review

Potential Drugs in COVID-19 Management

Amin Gasmi et al. Curr Med Chem. 2024.

Abstract

The SARS-CoV-2 virus first emerged in China in December 2019 and quickly spread worldwide. Despite the absence of a vaccination or authorized drug specifically developed to combat this infection, certain medications recommended for other diseases have shown potential effectiveness in treating COVID-19, although without definitive confirmation. This review aims to evaluate the existing literature on the efficacy of these medications against COVID-19. The review encompasses various potential treatments, including antiviral medications, anti-malaria and anti-rheumatic drugs, vaccines, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), antipyretic and analgesic medicines, antiparasitic drugs, and statins. The analysis also addresses the potential benefits and drawbacks of these medications, as well as their effects on hypertension and diabetes. Although these therapies hold promise against COVID-19, further research, including suitable product production or clinical testing, is needed to establish their therapeutic efficacy.

Keywords: COVID-19; Coronavirus; antibiotics; antivirals; hyperglycemia; hypertension; pandemic.; statins.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Zhou F.; Yu T.; Du R.; Fan G.; Liu Y.; Liu Z.; Xiang J.; Wang Y.; Song B.; Gu X.; Guan L.; Wei Y.; Li H.; Wu X.; Xu J.; Tu S.; Zhang Y.; Chen H.; Cao B.; Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020,395(10229),1054-1062 - DOI - PubMed
    1. Wu Z.; McGoogan J.M.; Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020,323(13),1239-1242 - DOI - PubMed
    1. Mahase E.; Long covid could be four different syndromes, review suggests. BMJ 2020,371,m3981 - DOI - PubMed
    1. Liu J.; Liu Y.; Xiang P.; Pu L.; Xiong H.; Li C.; Zhang M.; Tan J.; Xu Y.; Song R.; Neutrophil-to-lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage. J Transl Med 2020,18(1),206 - DOI - PubMed
    1. Cao Q.; Chen Y.C.; Chen C.L.; Chiu C.H.; SARS-CoV-2 infection in children: Transmission dynamics and clinical characteristics. J Formos Med Assoc 2020,119(3),670-673 - DOI - PubMed

MeSH terms